Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.

@article{Deecher2006DesvenlafaxineSA,
  title={Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.},
  author={Darlene C. Deecher and Chad E. Beyer and Grace Johnston and Jenifer A. Bray and Shambhu Shah and Magid A Abou-Gharbia and Terrance H. Andree},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2006},
  volume={318 2},
  pages={
          657-65
        }
}
The purpose of this study was to characterize a new chemical entity, desvenlafaxine succinate (DVS). DVS is a novel salt form of the isolated major active metabolite of venlafaxine. Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively. DVS showed weak binding affinity (62% inhibition at 100 microM… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 107 CITATIONS, ESTIMATED 46% COVERAGE

Spine Pain Care: A Comprehensive Clinical Guide

VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Desvenlafaxine succinate ameliorates visceral hypersensitivity but delays solid gastric emptying in rats.

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.

VIEW 7 EXCERPTS
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2004
2020

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 5 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES